Existing cancer therapy in narrow use shows significant activity against other cancers

A drug currently used in just 1% of cancers has significant potential against the remaining 99%, according to a new study. Ivosidenib, or AG-120, is currently used against cancers that have a mutation in the IDH1 gene. However, study results show that Ivosidenib is also effective against unmutated, or 'wild-type' IDH1. The protein coded by the IDH1 gene in cancers helps cancer cells survive in a stressful tumor environment, so any inhibitor medication that could weaken this defense mechanism is considered a promising therapy.

from Latest Science News -- ScienceDaily https://ift.tt/1PkxgS7

Comments

Popular posts from this blog

Seismic study reveals key reason why Patagonia is rising as glaciers melt

New method to detect and visualize sperm cells recovered from forensic evidence